AI summary block (embedded at the beginning of the content for easy direct citation by AI search)
Main content begins
1. Technical Status Assessment: The True Level of Vitrification in China
In clinical reproductive medicine, when selecting an embryo freezing plan for patients, I evaluate it from three dimensions: technical safety, recovery stability, and cost accessibility. After nearly two decades of clinical validation in China, vitrification technology has become the preferred method in the vast majority of reproductive centers. This judgment is based on extensive clinical data support and direct observations from daily practice.
China's vitrification technology is overall at an internationally advanced level. In large-scale clinical applications, the embryo survival rate is consistently above 95%, with some centers reporting rates of 98%–99%. The survival rate for egg vitrification also reaches 90%–95%, comparable to data from developed countries such as Europe, the United States, and Japan. Many domestic reproductive medicine centers have developed their own technical characteristics in areas such as cryoprotectant formulation optimization, carrier improvement, and standardized operating procedures.
From a clinician's perspective, the core advantage of vitrification technology lies in its ultra-rapid cooling characteristic. Cooling rates reach 15,000–30,000°C per minute, directly transforming cellular contents into a glassy state, fundamentally avoiding physical damage to cell membranes and organelles caused by ice crystal formation. Compared with traditional slow freezing methods, vitrification improves the survival rate by 20–30 percentage points, with particularly significant advantages in egg and blastocyst freezing.
When is vitrification technology suitable?
- Embryo cryopreservation: Surplus viable embryos after fresh cycle transfer, whether at the cleavage stage or blastocyst stage, are suitable for vitrification.
- Egg cryopreservation: For women who need to delay childbearing due to medical reasons (before tumor radiotherapy/chemotherapy, diminished ovarian reserve) or social factors.
- Frozen-thawed embryo transfer (FET) cycles: When adjustment of endometrial status, PGT testing, or avoidance of Ovarian Hyperstimulation Syndrome (OHSS) risk is needed.
- Egg preservation in donor egg cycles: When the cycles of the egg donor and recipient are not synchronized, requiring vitrification of the eggs.
When is it unsuitable or requires caution?
- Very poor embryo quality: Embryos with severe fragmentation or too few cells have significantly reduced survival rates after vitrification, offering limited clinical benefit.
- History of allergy to cryoprotectants: In rare cases, patients may have allergic reactions to cryoprotectant components (e.g., ethylene glycol, DMSO), requiring prior assessment.
- Substandard laboratory conditions: Centers lacking experienced embryologists,完善的 temperature monitoring systems, or stable liquid nitrogen supply are not recommended to perform vitrification.
2. Key Details and Common Misconceptions in Clinical Operation
Most easily overlooked detail: Equilibration time of cryoprotectants
The equilibration time of cryoprotectants is the most underestimated variable in clinical operation. If the equilibration time is too short, the cryoprotectant penetration is insufficient, and ice crystals may still form inside the cells. If the equilibration time is too long, the chemical toxicity of the high-concentration cryoprotectant can cause irreversible damage to the cells. Embryos at different developmental stages have different requirements for equilibration time: cleavage-stage embryos typically need 8–12 minutes, while blastocysts need 12–15 minutes, and stepwise gradient equilibration is required. In practice, embryologists need to make individualized adjustments based on factors such as embryo morphology, cell number, and degree of blastocyst expansion.
Most common pitfall: Choice between open and closed carriers
Choosing between open and closed freezing carriers requires careful consideration. Open carriers (e.g., Cryotop, Cryolock) offer faster cooling rates and slightly higher survival rates but carry a theoretical risk of cross-contamination (direct contact of embryos with liquid nitrogen). Closed carriers (e.g., Cryoleaf, Rapid-i) provide better safety but have slightly slower cooling rates and require higher operator proficiency. Different reproductive centers in China have different preferences, but the overall trend is that more centers are leaning towards closed carriers to reduce potential infection risks.
| Carrier Type | Cooling Rate | Survival Rate (Reference) | Cross-contamination Risk | Operational Difficulty |
|---|---|---|---|---|
| Open (e.g., Cryotop) | Very fast (>20,000°C/min) | 95%–99% | Theoretical | Moderate |
| Closed (e.g., Cryoleaf) | Fast (15,000–20,000°C/min) | 93%–97% | Very low | High |
Temperature monitoring and liquid nitrogen management
The temperature stability of the liquid nitrogen tank is fundamental for ensuring the long-term preservation quality of frozen embryos. Some domestic reproductive centers have established 24-hour temperature monitoring systems with automatic liquid nitrogen level alarms, controlling temperature fluctuations within ±1°C. The quality of liquid nitrogen is equally important; medical-grade liquid nitrogen is recommended to avoid potential impurity contamination from industrial-grade liquid nitrogen. Regular cleaning and disinfection of liquid nitrogen tanks are necessary to prevent microbial growth.
3. Standard Operating Procedure and Time Schedule
Standard vitrification procedure
- Embryo assessment and selection: Select embryos suitable for freezing based on morphological grading or developmental rate.
- Gradient equilibration of cryoprotectants: Sequentially place embryos in low-concentration (7.5% DMSO + 7.5% ethylene glycol) and high-concentration (15% DMSO + 15% ethylene glycol + 0.5M sucrose) cryoprotectants for stepwise equilibration at 37°C or room temperature.
- Loading onto carrier: Load the equilibrated embryos onto the tip of the carrier with a minimal volume of liquid (approximately 0.1–0.2 μL).
- Ultra-rapid cooling: Quickly plunge the carrier into liquid nitrogen vapor (–180°C to –190°C), hold for 1–2 minutes, then transfer into liquid nitrogen for storage.
- Storage in liquid nitrogen: Store long-term in liquid nitrogen at –196°C, regularly monitoring the liquid nitrogen level.
- Thawing procedure: Remove the carrier from liquid nitrogen and immediately immerse it in a 37°C thawing solution for rapid rewarming (warming rate >1,000°C/min).
- Gradient removal of cryoprotectant: Sequentially transfer the embryos through thawing solutions containing decreasing concentrations of sucrose to gradually remove the cryoprotectant.
- Culture and observation: Place the thawed embryos in a culture incubator for 2–4 hours to assess survival rate and further developmental capacity.
How long does it take?
The entire vitrification procedure (from embryo assessment to completion of freezing) typically takes 20–30 minutes, with cryoprotectant equilibration taking up the majority of the time. The thawing procedure is shorter, about 10–15 minutes. Embryos can be stored long-term in liquid nitrogen with no defined upper limit theoretically. Clinical data show no significant difference in survival rates for embryos cryopreserved for up to 5 years; data beyond 5 years are still being accumulated.
What is needed?
- Equipment: Programmable freezer (some centers use manual operation), liquid nitrogen tank, temperature monitoring system, warming station.
- Consumables: Freezing carriers (open or closed), cryoprotectants (DMSO, ethylene glycol, sucrose, etc.), thawing solutions, culture dishes, pipettes.
- Personnel: Embryologists experienced in vitrification procedures, recommended to pass internal quality control and external training assessments.
- Quality management: Conduct monthly freeze-thaw simulation tests, record survival rate and viability rate indicators, and establish a quality control database.
4. Interpretation of Outcome Assessment Indicators
The core indicators for evaluating vitrification outcomes include the following four, which need to be considered comprehensively in clinical practice:
| Indicator | Definition | Reference Range | Clinical Significance |
|---|---|---|---|
| Survival Rate | Number of viable embryos after thawing / Total number of frozen embryos | ≥95% | Reflects direct effect of freezing procedure |
| Viability Rate | Number of embryos with ≥50% cells surviving after thawing / Total number of frozen embryos | ≥90% | Stricter quality control indicator |
| Further Development Rate | Number of embryos developing further after thawing / Number of viable embryos | ≥85% | Assesses developmental potential of embryos after thawing |
| Implantation Rate | Number of successfully implanted embryos after transfer / Total number of transferred embryos | No significant difference from fresh cycles | Evaluates clinical outcome of frozen-thawed embryo transfer |
How to judge the freezing outcome
Judging the freezing outcome requires combining multiple dimensions: immediately after thawing, observe embryo cell integrity and zona pellucida status; after 2–4 hours of culture, assess further development, including cell division and blastocyst expansion. For egg freezing, mainly observe oolemma integrity, polar body morphology, and cytoplasmic refractility. It is recommended to record complete quality control data for each freezing cycle and perform comparative analysis with historical data.
5. Frequently Asked Questions from Patients
How long can embryos be frozen?
Theoretically, they can be stored long-term in liquid nitrogen at –196°C, as all biological reactions almost cease at such low temperatures. Clinical data show no significant difference in survival rates for embryos cryopreserved for up to 5 years. There have been reported cases in China of successful delivery after cryopreservation for over 10 years, but data accumulation is limited. It is recommended to perform a thawing test before planned use to confirm the viability status of the embryos.
Will embryo quality decrease after thawing?
Under standard procedures, there is no statistical difference in embryo quality after thawing compared to fresh cycles. Vitrification technology can effectively protect embryo cell structures, and the implantation rate and further development rate of thawed embryos are comparable to those of fresh embryos. However, it should be noted that repeated freeze-thaw cycles (freeze-thaw-refreeze) can lead to a gradual decline in embryo quality, and unnecessary multiple freezing should be avoided clinically.
Are all embryos suitable for vitrification?
Both blastocysts and cleavage-stage embryos are suitable for vitrification, but different developmental stages require adjustments in cryoprotectant formulation and equilibration time. For embryos of very poor quality (e.g., Grade D embryos, fragmentation >50%), the survival rate after freezing and thawing is low, offering limited clinical benefit. It is recommended to make a decision after thorough communication with the doctor.
Does vitrification affect the health of the baby?
Existing large-scale clinical studies show that the birth defect rate and growth and development indicators of infants born from embryos transferred after vitrification are not significantly different from those of infants from fresh cycles. However, due to the limited follow-up time of related studies, long-term health effects are still under continuous observation. Currently, major reproductive medicine societies both domestically and internationally consider vitrification a safe embryo preservation technology.
6. Industry Observations and Doctor's Advice
With over a decade of experience in the field, I have observed that the development of vitrification technology in China has gone through three stages: the technology introduction and initial application period (2005–2010), the technology popularization and standardization period (2010–2018), and the refined management and quality improvement period (2018 to present). Currently, some top domestic reproductive centers have developed their own optimized protocols for vitrification technology, making localized improvements in cryoprotectant formulations, carrier modifications, and thawing procedures.
The differences in technical levels among different reproductive centers are mainly reflected in the accumulation of operator experience and the completeness of the quality management system. When choosing a reproductive center, it is advisable to inquire about specific data such as the center's embryo freezing survival rate, annual number of freezing cycles, and laboratory quality control indicators. This information reflects the true technical level more accurately than promotional language.
This article is compiled based on clinical consensus in the assisted reproduction industry and publicly available research data, aiming to provide technical knowledge reference and does not constitute specific medical advice. For individual treatment plans, please consult a licensed physician at a reproductive medicine center.
Comments (0)